艾迪注射液对结肠癌化疗患者T淋巴细胞亚群水平及生活质量的影响(1)
[摘要] 目的 探討艾迪注射液对结肠癌化疗患者T淋巴细胞亚群水平及生活质量的变化。 方法 以我院2015年2月～2017年5月收治的86例结肠癌患者为研究对象，采用随机数字表法分为化疗组(常规化疗，n=43)和结合组(常规化疗+艾迪注射液，n=43)，比较两组的近期疗效、治疗前后T淋巴细胞亚群水平、生活质量变化和不良反应情况。 结果 结合组与化疗组CR、PR、SD和PD分布比较差异显著(P<0.05)，前者临床获益率为72.09%，后者为51.16%，差异有统计学意义(P<0.05)；治疗后结合组T淋巴细胞亚群水平和生活质量评分均无明显改变(P>0.05)，化疗组CD3+、CD4+、CD4+/CD8+和生活质量评分均降低(P<0.05)，CD8+均升高(P<0.05)，且治疗后结合组与化疗组比较有统计学差异(P<0.05)；结合组各项不良反应发生率均低于化疗组(P<0.05)，且两组分级比较差异均有统计学意义(P<0.05)。 结论 对结肠癌化疗患者应用艾迪注射液能够改善近期疗效，避免免疫功能损害和生活质量下降，还可减少并减轻化疗所致的不良反应。
[关键词] 艾迪注射液；结肠癌；化疗；T淋巴细胞亚群；生活质量
[中图分类号] R735 [文献标识码] A [文章编号] 1673-9701(2018)13-0010-04
Effect of Aidi injection on T lymphocyte subsets and quality of life in patients with colon cancer
WU Guiyang CHEN Zaiping YE Fubo ZHU Xiongwen YUAN Shichao
Department of Gastrointestinal Surgery， Taizhou Municipal Hospital in Zhejiang Province， Taizhou 318000， China
[Abstract] Objective To investigate the changes of T lymphocyte subsets and quality of life after administrating Aidi injection in patients with colon cancer. Methods A total of 86 patients with colon cancer admitted to our hospital from February 2015 to May 2017 were enrolled in this study. The patients were divided into chemotherapy group (43 patients， conventional therapy) and combination group (43 cases， conventional chemotherapy+Aidi injection) by random number table. Compared the recent curative effect， level of T lymphocyte subsets， changes of quality of life and adverse reactions before and after treatment. Results There were significant differences in the distribution of CR， PR， SD and PD between the combination group and the chemotherapy group(P<0.05). The former had a clinical benefit rate of 72.09% and the latter was 51.16%. The difference was statistically significant(P<0.05). There was no significant difference in the level of T lymphocyte subsets and quality of life in the combination group after treatment(P>0.05). The CD3+， CD4+， CD4+/CD8+ and scores of quality of life in the chemotherapy group were significantly lower(P<0.05) after treatment， CD8+ increased in both groups， and there was statistical difference between the combination group and the chemotherapy group after treatment(P<0.05). The incidence of adverse reactions in the combination group was lower than that in the chemotherapy group(P<0.05) and the difference of classification comparison was also statistically significant(P<0.05). Conclusion The use of Aidi injection in colon cancer patients with chemotherapy can improve the short-term curative effect， avoid the damage of immune function and reduction of the quality of life， and relieve and reduce the adverse reactions caused by chemotherapy., http://www.100md.com(吴贵阳 陈再平 叶甫波 朱雄文 袁世超)
[关键词] 艾迪注射液；结肠癌；化疗；T淋巴细胞亚群；生活质量
[中图分类号] R735 [文献标识码] A [文章编号] 1673-9701(2018)13-0010-04
Effect of Aidi injection on T lymphocyte subsets and quality of life in patients with colon cancer
WU Guiyang CHEN Zaiping YE Fubo ZHU Xiongwen YUAN Shichao
Department of Gastrointestinal Surgery， Taizhou Municipal Hospital in Zhejiang Province， Taizhou 318000， China
[Abstract] Objective To investigate the changes of T lymphocyte subsets and quality of life after administrating Aidi injection in patients with colon cancer. Methods A total of 86 patients with colon cancer admitted to our hospital from February 2015 to May 2017 were enrolled in this study. The patients were divided into chemotherapy group (43 patients， conventional therapy) and combination group (43 cases， conventional chemotherapy+Aidi injection) by random number table. Compared the recent curative effect， level of T lymphocyte subsets， changes of quality of life and adverse reactions before and after treatment. Results There were significant differences in the distribution of CR， PR， SD and PD between the combination group and the chemotherapy group(P<0.05). The former had a clinical benefit rate of 72.09% and the latter was 51.16%. The difference was statistically significant(P<0.05). There was no significant difference in the level of T lymphocyte subsets and quality of life in the combination group after treatment(P>0.05). The CD3+， CD4+， CD4+/CD8+ and scores of quality of life in the chemotherapy group were significantly lower(P<0.05) after treatment， CD8+ increased in both groups， and there was statistical difference between the combination group and the chemotherapy group after treatment(P<0.05). The incidence of adverse reactions in the combination group was lower than that in the chemotherapy group(P<0.05) and the difference of classification comparison was also statistically significant(P<0.05). Conclusion The use of Aidi injection in colon cancer patients with chemotherapy can improve the short-term curative effect， avoid the damage of immune function and reduction of the quality of life， and relieve and reduce the adverse reactions caused by chemotherapy., http://www.100md.com(吴贵阳 陈再平 叶甫波 朱雄文 袁世超)
参见：首页 > 医疗版 > 疾病专题 > 消化内科 > 肠道疾病 > 类癌及类癌综合征 > 结、直肠癌